Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
STRO Sutro Biopharma
7.000+0.130+1.89%
Close
02/07 16:00 ET
High
7.050
Open
6.870
Turnover
3.09M
Low
6.670
Pre Close
6.870
Volume
444.73K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Are Investors Undervaluing Sutro Biopharma, Inc. (NASDAQ:STRO) By 46%?
JMP Securities Remains a Buy on Sutro Biopharma (STRO)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zynex (ZYXI), Sutro Biopharma (STRO) and Amryt Pharma (AMYT)
Sutro Biopharma (NASDAQ:STRO) PT Raised to $25.00 at Truist Financial
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its target price upped by stock analysts at Truist Financial from $21.00 to $25.00 in a research note issued to investors on Friday, The Fly reports. T
Sutro Biopharma Price Target Raised to $25.00/Share From $21.00 by Truist Securities
Sutro Biopharma Is Maintained at Buy by Truist Securities
Sutro Biopharma Is Maintained at Buy by Truist Securities
Sutro Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/13/2023 225.95% Truist Securities $21 → $25 Maintains Buy 01/10/2023 134.68% Piper Sandler $16 → $18 Ma
Truist Securities Maintains Buy on Sutro Biopharma, Raises Price Target to $25
Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and raises the price target from $21 to $25.
Sutro Biopharma (NASDAQ:STRO) Price Target Raised to $18.00
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its target price boosted by Piper Sandler from $16.00 to $18.00 in a report published on Tuesday morning, The Fly reports. They currently have an overwe
Sutro Biopharma (NASDAQ:STRO) Given New $18.00 Price Target at Piper Sandler
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its target price lifted by Piper Sandler from $16.00 to $18.00 in a research report released on Tuesday morning, The Fly reports. They currently have an
Company Overview
More
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
CEO： Mr. William J. Newell
Market： NASDAQ
Listing Date： 09/27/2018
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet